welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Inhibiting NF-κB improves heart function in a mouse model of Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a devastating genetic disease that impairs cardiac and skeletal muscle development. People with DMD gradually lose ambulation in childhood, acquire respiratory and heart failure in young adulthood and succumb to the disease by their mid-thirties. Until recently, there has been no effective treatment for the characteristic muscle-wasting progression of this disease. Provisional FDA approval of the first DMD therapy (eteplirsen) and improved disease management strategies have extended the life span of DMD patients and expanded the field of DMD research into later-stage outcomes such as cardiomyopathy (heart failure).
rareRelated
-
The Relationship between Bone Mineral Density and Cardiovascular Function in Duchenne Muscular Dystrophy: A Retrospe...Objective: The objective of this retros...
-
Meilan M. Rutter, MDMeilan Rutter is board-certified in pedi...
-
CureDuchenne – FacebookCureDuchenne is a nonprofit organization...
-
Eric Hoffman, PhDDr. Hoffman has worked on Duchenne Muscu...
-
Duchenne Muscular Dystrophy Research Fund (DMDfund)Duchenne Muscular Dystrophy Research Fun...
-
Joline Dalton, MS, CGCJoline Dalton is a board certified genet...
-
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyIn Duchenne muscular dystrophy (DMD), pr...
